Mark your calendars for the year. DM to be added to our mailing list and never miss a meeting: @crisbergerot.bsky.social @realbowtiedoc.bsky.social @tingtingzhang.bsky.social @ericroeland.bsky.social @mazietsangmd.bsky.social @ascocancer.bsky.social @darcyburbage.bsky.social @rsedhom.bsky.social

This Thursday!! Join us for our kick-off meeting with our leaders @crisbergerot.bsky.social and @realbowtiedoc.bsky.social. DM for link @tingtingzhang.bsky.social @fionnualacrowley.bsky.social @ericroeland.bsky.social @mazietsangmd.bsky.social @ascocancer.bsky.social @darcyburbage.bsky.social

New guideline alert for oncology professionals! 🚨 ASCO & ONS just dropped their "Management of Antineoplastic Extravasation" guideline. Get the latest on antidotes, thermal compresses, and surgical referrals for extravasation. Read it here: brnw.ch/21wVTFD

📢 Join us for ASPIRE Consortium's Global Session 🌍 Collaborating Across Europe: Advancing Care for irAEs 🎙️ Featuring @drjnaidoo.bsky.social + panel 📅 Sept 15, 2025 🕒 Time: 15:00–16:00 (Central US Time) 💻 Zoom Link: partners.zoom.us/j/82978479128 🔢 Meeting ID: 829 7847 9128 @ascocancer.bsky.social

For those dealing with the treatment-induced, menopause-y side effects of treatment for HR+ breast cancer like hot flashes and REALLY crappy sleep, this is a very interesting (and hopeful!) study #CanSky #MakeCancerLessShitty #QoL

Phase 3 #SymptomScience @nejm.org RCT of elinzanetant vs placebo for moderate-to-severe vasomotor symptoms in HR+ #breast cancer (n=474) @ascocancer.bsky.social @cancercaremascc.bsky.social @hoperugo.bsky.social @coffeemommy.bsky.social @stage4kelly.bsky.social www.nejm.org/doi/full/10....

A summer 🌞 of firsts. Overjoyed to share my #inaugural editorial with 🥇 peer mentor @mazietsangmd.bsky.social in JCO-OP @ascocancer.bsky.social 🤖⏱️ #Wearable tech is transforming #SuppOnc and how we assess patient fitness 🏋️‍♀️ 🔗: ascopubs.org/doi/10.1200/...

In @nytopinion.bsky.social “My son’s life depends on government assistance,” writes Rachel Roth Aldhizer. “Recent cuts to Medicaid at both the federal and state levels mean millions of families like mine could soon be at a loss for how to care for our disabled loved ones.”

Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology. Learn more: bit.ly/45wiiQ6

A pleasure and an honor to join @fumikochino.bsky.social & Dr. Ethan Ludmir in this @ascocancer.bsky.social conversation on incomplete reporting and toxicity- minimizing language in oncology! 💗

Excited to head out this week to share the #BestofASCO in #pallonc and #supponc later this week. Join us! @fumikochino.bsky.social @tingtingzhang.bsky.social @ericroeland.bsky.social @darcyburbage.bsky.social @oncoalert.bsky.social @weoncologists.bsky.social @pallonccop.bsky.social

Thank you Sesttle! After a fabulous time at #MASCC25, I'm heading home with a full heart & mind. Grateful to all those working to improve supportive care in cancer & thrilled to have had yet another opportunity to share our advocate-led research on the main stages! Safe travels to all 💗

🚨CMS just announced a model to introduce new #priorauthorization barriers to Traditional Medicare (which classically hasn't faced any). We need less #priorAuth, not more. Don't let this title fool you. This is a "fix" for a problem that doesn't exist. @ascocancer.bsky.social @astro-org.bsky.social

Kicking off Day 2 of #MASCC25 with "Workshop 3: Beyond Survivorship 101: Building advanced skills in survivorship care" led by Dr Larissa Nekhlyudov, @darcyburbage.bsky.social and @michael-jefford.bsky.social

"Every patient with cancer needs supportive care" Good morning #mascc25! We're in Seattle for the premiere conference in #supponc discussing toxicity management and quality of life. But first... breakfast and coffee at Pike Place Market ☕️🥐🍳 @cancercaremascc.bsky.social

Shout out to @stage4kelly.bsky.social on her e-poster presentation on the Patient Centered Dosing Initiative at #MASCC25 And kudos to all co-authors and supporters of PCDI

Kudos and gratitude to the organizers, attendees, and fellow faculty members for today's Workshop 1: Partnering with patients in managing chronic toxicities of cancer and its treatment #MASCC25 @maryamlustberg.bsky.social @tingtingzhang.bsky.social @ericroeland.bsky.social @brueraeduardo.bsky.social

Grateful for the insights and discussions shared with the stellar panelists and engaged audience at #MASCC25 workshop for cancer treatment toxicities. @maryamlustberg.bsky.social @ericroeland.bsky.social @coffeemommy.bsky.social and Dr Eduardo Bruera with screenshot from @stage4kelly.bsky.social

In 2025, we welcome and congratulate our inaugural cohort of MASCC Fellows (FMASCC). Fellow status is awarded to individuals who have made a sustained contribution to MASCC and demonstrated a continued high level of excellence in cancer supportive care practice and/or research. #MASCC25

@drnataliagandur.bsky.social @kjankovic.bsky.social @elisaagostinetto.bsky.social @joanmancusombc.bsky.social @ascocancer.bsky.social @crisbergerot.bsky.social @tingtingzhang.bsky.social @fionnualacrowley.bsky.social @ericroeland.bsky.social @mazietsangmd.bsky.social @darcyburbage.bsky.social

What every doctor and nurse should know about radiation oncology when caring for individuals with serious illness. #medsky geripal.org/what-you-sho...

@coffeemommy.bsky.social @stage4kelly.bsky.social @bogda-koczwara.bsky.social @maryamlustberg.bsky.social @tingtingzhang.bsky.social @joannebowen.bsky.social

🚀 Stay ahead in cancer care!✨ For the latest @ascocancer.bsky.social #guidelines, check out this must-bookmark webpage: ascopubs.org/guidelines. Plus, don't miss the ASCO Guidelines App & cutting-edge AI assistant! Go-to resources for informed decisions💡 @latinamd.bsky.social @beverlymoy.bsky.social

It's been my greatest joy to be a part of this community in my #earlycareer. Thanksful to have had the priveldge of leading with Dr @mazietsangmd.bsky.social and looking forward to this year with Dr @crisbergerot.bsky.social #pallonc #supponc @tingtingzhang.bsky.social @ericroeland.bsky.social

🎙️New #ASCO25 podcast: I was delighted to speak to BreastCancer.org to summarize my @ascocancer.bsky.social presentation on how doctors can help address the affordability gap. And what people with cancer should know about #financialToxicity in #breastcancer #bcsm www.breastcancer.org/podcast/brea...

See you soon my @pallonccop.bsky.social friends. Here is a reel of our #ASCO25 gathering. Dr Thomas Smith at Johns Hopkins gave a great lecture and the president of @aahpm.bsky.social Dr Arif Kamal followed with a commentary on fostering a community of leaders. @ericroeland.bsky.social

Melanoma orals #8 ➡️ S2000 enco bini nivo vs ipi nivo in symptomatic melanoma brain mets ➡️First randomized trial in symptomatic brain mets ➡️Significant PFS improvement with triple therapy over ipi nivo ➡️No significant OS benefit Zeynep Eroglu, Moffitt #ASCO25 @ascocancer.bsky.social

“What we’re saying isn’t sexy or exciting –we can’t promise a cure. The drugs we give have side-effects & some people still die.” Dr @lizoriordan.bsky.social @ascocancer.bsky.social #Misinformation promises cure w/o side effects (or evidence). We need to be better communicators; lives are at risk.

#ASCO25: As we bid adieu to Chicago, reinvigorated from time with friends & colleagues united in a common goal against cancer... Mark your calendars to return for #ASCOQLTY25. Let’s KEEP making a difference in cancer together! ⏰ Abstracts due 6/10‼️ 📆 Chicago Fri/Sat 10/10-11

🚀 That's a wrap #ASCO25! Join ASCO’s #ASPIRE Community of Practice, the go-to hub for clinicians addressing immune-related toxicities! 🌟 FREE access for non-oncologists (for a limited time) 💬 Engage in virtual meetings, expert discussions, and access curated content! docs.google.com/forms/d/1zfl...

Multiple new agents with mechanisms other than immunotherapies under investigation for metastatic melanoma: ➡️ new BRAF targeting agents ➡️ PRMT5 inhibition ➡️ ROR2 ADC -Meredith McKean, Sarah Cannon #ASCO25 @ascocancer.bsky.social

Rapid melanoma oral #7 ➡️ 5 year outcomes with lifileucel -mDOR 36.5m -31.3% of responders with sustained response -3 pts with PR that deepened after about a year -AEs within first 3 m and drop off dramatically Theresa Medina U Colo #ASCO25 @ascocancer.bsky.social

Much less clarity on whether or not to continue systemic immunotherapy after pCR following neoadjuvant therapy The people have spoken, and they are undedecided - more work to do! #melsm #ASCO25

Alright y’all - last day of #irAE content at #ASCO25 @aspire-cop.bsky.social @ascocancer.bsky.social Monday 6/2 11:30a Bi/Multi-specific Antibodies S406 ➡️Giuseppe Curigliano ➡️Enriquita Felip ➡️Funda Meric Bernstam 3p Beyond Checkpoint E450b ➡️me 😇 ➡️Evan Lipson ➡️Jason Luke

Melanoma rapid oral #9 ➡️ OBX-115, engineered TIL with membrane bound IL15 regulated with acetazolamide -for 6pt receiving RP2D, 67% ORR, 1 CR, 100% DCR -mDOR not reached Jason Chesney U Louisville and @drbetofmdphd.bsky.social @stanford-cancer.bsky.social #ASCO25 @ascocancer.bsky.social

Where's my #earlybirds at? 🐦🪱 Please join us 7:30a in East Building (Across the Sky Bridge) down on 2nd floor in room E253cd We'll have legends in #pallonc like @ericroeland.bsky.social imparting their wisdom and vision for the next gen of #supponc We will bring the breakfast!

Acral melanoma pearls -adjuvant therapy not effective -targeted therapy with responses (not enough data to clearly choose IO vs targeted as 1L imho) -alternative regimens with efficacy in Asia (different biology than US?) Keri Kendra @ohiostatemed.bsky.social #ASCO25 @ascocancer.bsky.social

Plenary #1 involves checkpoint inhibition…count with me here 🤔 #ASCO25

3️⃣ Weeks to go to #ASCO25 !. The schedule can be so overwhelming.. Here is my suggested schedule for thoracic trainees. Start making your schedule in the @asco app today and bring comfortable 👟 @hemoncfellows @hemoncmiami #lcsm

#ASCO25 Top Lung Cancer Abstract Presentations to watch for Trainees (a working list) Updates on #perioperative and #targetedtherapy trials. #CM77T #CM816, #NEOADAURA, #ALNEO, #SACHI, #KRYSTAL-2 #lcsm @hemoncfellows @hemoncmiami @sylvestercancer

So many abstracts so little time⌚! Here are #ASCO25 Top Lung Cancer Abstract Presentations to watch for -Part 1 Not a lot of new drugs but important updates on #perioperative and #targetedtherapy trials. Full abstracts available 5/22. #lcsm @hemoncfellows @hemoncmiami @sylvestercancer

👏👏On making guidelines more accessible for busy oncologists: @ASCO and Google create ‘walled garden’ AI tool for doctors to query group’s guidelines www.statnews.com/2025/05/21/a... via @statnews.com

In just 2 days, join us during #ASCO25 for a special session on "Leveraging Social Media for Your Career" with @marklewismd ▶️ Finding your voice (among all the noise) ▶️ Expand your network ▶️ Promote your research 📆 Friday, May 30th ⏰ 3:00-3:45PM 📍Hall C, ASCO Trainee Lounge @ASCOTECAG

Starting soon! More great #irAE content at #ASCO25, including CAR-T and BiTES @kmittalmd.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social #ASPIRE

Thrilled to see this conversation on the #ASCO25 mainstage Cannabis IS being used by patients for supportive care and we NEED to be talking about it from a benefit / risk standpoint @ericroeland.bsky.social Dr. Ilana Braun, Stacey Blansky, and @ishwaria.bsky.social #SuppOnc #SurvOnc

Happening soon! So excited to join Dr Suneja and Dr Green in a few hours to share our insights in Navigating 🧭 #EarlyCareer here at #ASCO25 Topics include: 📃 Contracts 🤝 Networking 🪜 Mentorship 🔀 Switching Gears ⚖️ Finding Balance Hope to see you there! 🔗: meetings.asco.org/2025-asco-an...

Did you know the ICD10 codes to identify patients experiencing immunotherapy toxicity? @kmittalmd.bsky.social presents these codes as a system-based approach to capture #irAE impact @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @mazietsangmd.bsky.social @ascocancer.bsky.social

@kmittalmd.bsky.social presents #ASPIRE #ASCO25 community united in "Advancing Clinical Care, Research, and Advocacy in Immunotherapy-Related Adverse Events" #irAE @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @ascocancer.bsky.social @mazietsangmd.bsky.social @advocatecollab.bsky.social

🎉 Big news! Today marks the first gathering of ASCO's latest COP—ASPIRE! 🚀 Join us for the #ASPIRE COP meeting TODAY from 4-6 PM CST in Room E253cd. Let’s connect and collaborate! Don’t miss out! 🤝✨ @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social

We are very excited for our in person meeting on Monday at #ASCO25. If you’re interested in whole person care for patients with cancer please join us! @ascocancer.bsky.social @crisbergerot.bsky.social @ericroeland.bsky.social @realbowtiedoc.bsky.social @darcyburbage.bsky.social